Clinical investigator associated with study at Alembic’s bioequivalence unit gets U.S. FDA warning letter
Alembic Pharmaceuticals announced that the U.S. FDA issued a warning letter to a clinical investigator involved in a bioequivalence study at their Vadodara facility. The company stated the issue relates to informed consent documentation rather than data integrity.
Why it matters
Regulatory compliance in pharmaceutical research is critical for maintaining drug safety standards and market access in the United States.
Alembic Pharmaceuticals on Monday said the U.S. Food and Drug Administration (U.S. FDA) has issued a warning letter to the clinical Investigator associated with a bioequivalence study conducted at the company’s bioequivalence facility in Vadodara.
The warning letter pertains to observation regarding informed consent form (ICF) in relation to a bioequivalence study. The observations do not relate to data integrity. Based on the company’s preliminary assessment, the warning letter does not impose any restriction on the operations of the bioequivalence facility. It is coordinating with the Clinical Investigator for submission of an appropriate response to the U.S. FDA within the stipulated timeline, Alembic said in a filing.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in